Acute Myeloid Leukemia (non-APL) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	surveillance
Linked regimen	`None`

ID	`IND-ASCT-SECONDARY-MDS-AML-PREVENTION-OBSERVATION`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-NCCN-AML-2025`

Notes

STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode. v0.3 wave-N niche pathway alternative track (ASCT-survivor t-MDS/t-AML). Sibling — IND-ASCT-SECONDARY-MDS-AML-PREVENTION-SURVEILLANCE. §15.2 C4 ≥2-tracks invariant.

Used By

Indication

IND-ASCT-SECONDARY-MDS-AML-PREVENTION-SURVEILLANCE - IND-ASCT-SECONDARY-MDS-AML-PREVENTION-SURVEILLANCE

Red flag

RF-IATROGENIC-ASCT-SECONDARY-MDS-AML-PREVENTION - History of autologous stem-cell transplantation (ASCT) as consolidation or salvage therap...